Back to discover

Protein / target

Platelet-derived growth factor receptor alpha

Encoded byPDGFRAP16234Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
15
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Transmembrane receptor protein tyrosine kinase

Strongest disease association

GIST-plus syndrome

Via encoding gene PDGFRA · Genetic evidence · score 0.84

Therapeutic position

Established drug target

Small molecules and antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis.

View complete UniProt function annotation

Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor

Subcellular location

Cell membraneCell projection, ciliumGolgi apparatus
Domains and Gene Ontology detail (58)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3Ig-like C2-type 4Ig-like C2-type 5Protein kinase

Gene Ontology

  • Ccilium
  • Ccytoplasm
  • Cendoplasmic reticulum membrane
  • Cexternal side of plasma membrane
  • CGolgi apparatus
  • Cmembrane
  • Cmicrovillus
  • Cnucleus
  • Cplasma membrane
  • Cprotein-containing complex
  • Creceptor complex
  • FATP binding

1089 aa · 123 kDa · 3 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGO · ReactomeCell migrationUniProt · GOGrowth-factor signallingGOReceptor tyrosine kinase signallingGOOncogenic signallingReactomeHaemostasisUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation
  • ·positive regulation of cell proliferation by VEGF-activated platelet derived growth fact…
  • ·PIP3 activates AKT signaling
  • ·PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling

Cell migration

  • ·Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC…
  • ·cell chemotaxis
  • ·cell migration
  • ·positive regulation of cell migration

Growth-factor signalling

  • ·platelet-derived growth factor binding
  • ·vascular endothelial growth factor binding
  • ·platelet-derived growth factor receptor signaling pathway
  • ·positive regulation of cell proliferation by VEGF-activated platelet derived growth fact…

Receptor tyrosine kinase signalling

  • ·transmembrane receptor protein tyrosine kinase activity
  • ·cell surface receptor protein tyrosine kinase signaling pathway

Oncogenic signalling

  • ·Constitutive Signaling by Aberrant PI3K in Cancer

Haemostasis

  • ·Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC…
  • ·negative regulation of platelet activation
  • ·platelet aggregation
  • ·positive regulation of cell proliferation by VEGF-activated platelet derived growth fact…
View underlying pathways (13)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

PDGFCPDGFAPDGFBPDGFDPTPN11PIK3R1PIK3CAPDGFRBPLCG1EGFPDGFRA

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

5 medicines · 9 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Gastrointestinal Stromal Tumors2 medicines
Carcinoma, Renal Cell1 medicine
Colorectal Neoplasms1 medicine
Leukemia, Myeloid, Acute1 medicine
Mastocytosis1 medicine
Mastocytosis, Systemic1 medicine
Neuroendocrine Tumors1 medicine
Sarcoma1 medicine
Broader indication categories (1)

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

15 medicines meet Open Targets' target-level approved-medicine definition; the 5 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

5

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

olaratumab
Narrow target profileApprovedAntagonist

Platelet-derived growth factor receptor alpha antagonist

Indicated for Sarcoma, Neoplasms

Direct interaction with this protein · Only this protein recorded as a target

avapritinib
Narrow target profileApprovedInhibitor

Platelet-derived growth factor receptor alpha inhibitor

Indicated for Gastrointestinal Stromal Tumors, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

sunitinib
ApprovedInhibitor

Platelet-derived growth factor receptor alpha inhibitor

Indicated for Carcinoma, Renal Cell, Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, Neoplasms

Direct interaction with this protein · 1 of 9 recorded protein targets — broad pharmacology

regorafenib
ApprovedInhibitor

Platelet-derived growth factor receptor inhibitor

Indicated for Colorectal Neoplasms, Neoplasms

Acts on a complex — shared with PDGFRB · 1 of 18 recorded protein targets — broad pharmacology

midostaurin
ApprovedInhibitor

Platelet-derived growth factor receptor inhibitor

Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms

Acts on a complex — shared with PDGFRB · 1 of 16 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PDGFRA

Gene-level evidence surfaced through the gene PDGFRAthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Gastrointestinal Stromal Tumors
0.98Well supported

Clinical evidence dominant · Open Targets 0.82

Neoplasms
0.88Well supported

Clinical evidence dominant · Open Targets 0.64

GIST-plus syndrome
0.83Well supported

Genetic evidence dominant · Open Targets 0.74

Leukemia, Myeloid, Acute
0.80Well supported

Clinical evidence dominant · Open Targets 0.63

Idiopathic Pulmonary Fibrosis
0.78Well supported

Clinical evidence dominant · Open Targets 0.60

View evidence synthesis (5)
Gastrointestinal Stromal TumorsWell supported
0.98
agreement 0.901.00
Clinical29%Genetic26%Somatic mutation20%Pathway15%Literature6%Animal model4%Genetic literaturedup

Open Targets aggregate 0.82 · 6 independent evidence families · 1 not counted as duplicate

NeoplasmsWell supported
0.88
agreement 0.770.99
Clinical49%Pathway27%Somatic mutation14%Literature10%

Open Targets aggregate 0.64 · 4 independent evidence families

GIST-plus syndromeWell supported
0.83
agreement 0.710.95
Genetic100%Genetic literaturedup

Open Targets aggregate 0.74 · 1 independent evidence family · 1 not counted as duplicate

Leukemia, Myeloid, AcuteWell supported
0.80
agreement 0.680.92
Clinical63%Somatic mutation27%Literature10%

Open Targets aggregate 0.63 · 3 independent evidence families

Idiopathic Pulmonary FibrosisWell supported
0.78
agreement 0.650.91
Clinical77%Animal model17%Literature6%

Open Targets aggregate 0.60 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Gastrointestinal Stromal Tumors0.82
GIST-plus syndrome0.74
Neoplasms0.64
Leukemia, Myeloid, Acute0.63
Soft tissue sarcoma0.61
Sarcoma0.61
Carcinoma, Renal Cell0.60
Idiopathic Pulmonary Fibrosis0.60
Carcinoma, Non-Small-Cell Lung0.60

Drug development

33 compounds recorded · 15 approved · 18 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 5 drugs that target this protein in Forefront's canonical graph (5 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
SU-014813Phase 2
FAMITINIBPhase 3
TAK-593Phase 1
CEDIRANIBApproval
OLARATUMABApproval
DOVITINIBPhase 3
RIPRETINIBApproval
PAZOPANIBApproval
ORANTINIBPhase 3
SUNITINIB MALATEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesStrong

Approved Drug and UniProt loc high conf support this modality.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (13)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule BinderOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ACTIVE_NOT_RECRUITING · via regorafenib · NCT05395741

ACTIVE_NOT_RECRUITING · via sunitinib · NCT02465060

ACTIVE_NOT_RECRUITING · via sunitinib · NCT01396408

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 4 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. New publication2024-06-04
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 69 citations · Europe PMC · via regorafenib

  2. New publication2024-05-03
    Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.

    PLoS computational biology · 2024 · 10 citations · Europe PMC · via sunitinib

  3. New publication2024-01-05
    Genomic profiling in GIST: Implications in clinical outcome and future challenges.

    Neoplasia (New York, N.Y.) · 2024 · 20 citations · Europe PMC · via sunitinib

  4. New publication2021-03-01
    Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    The New England journal of medicine · 2021 · 1,297 citations · Europe PMC · via sunitinib

  5. Regulatory approval2021-02-11

    Approval: Sunitinib Accord (EMA)

    ema · regulatory · ema · via sunitinib

  6. Regulatory approval2020-09-24

    Approval: Ayvakyt (EMA)

    ema · regulatory · ema · via avapritinib

  7. New publication2019-02-16
    Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    The New England journal of medicine · 2019 · 2,427 citations · Europe PMC · via sunitinib

  8. New publication2018-03-21
    Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

    The New England journal of medicine · 2018 · 3,404 citations · Europe PMC · via sunitinib

  9. Regulatory approval2017-09-18

    Approval: Rydapt (EMA)

    ema · regulatory · ema · via midostaurin

  10. New publication2016-12-06
    Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lancet (London, England) · 2017 · 2,767 citations · Europe PMC · via regorafenib

  11. Regulatory approval2013-08-26

    Approval: Stivarga (EMA)

    ema · regulatory · ema · via regorafenib

  12. Regulatory approval2006-07-19

    Approval: Sutent (EMA)

    ema · regulatory · ema · via sunitinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Related literature

1

Papers indexed under “Receptor, Platelet-Derived Growth Factor alpha” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.

Genomic profiling in GIST: Implications in clinical outcome and future challenges.

Calderillo-Ruíz G · Neoplasia (New York, N.Y.) · 2024

Europe PMC literature, reached through a MeSH descriptor linked to this protein.